此内容来自:xinyabo体育app

宏:股权衍生品2008首先

首先是第二次直接年份的是由加布里埃拉·贝斯,伊夫伦尔·伯格和赛勒·德尔帕德飞行的九部队团队。该集团从雷曼兄弟搬到巴克莱。

Gabriela Baez.

Maneesh Deshpande.

Evren Ergin.

Gabriela Baez,Maneesh Deshpande,Evren Ergin&Team

巴克莱

第二队

Phillip Mackintosh,爱德华汤姆和团队瑞士信贷

第三队

John Marshall&Team高盛

赛跑者

Heiko Ebens&TeamMerrill Lynch.

In first place for a second straight year is the nine-member team piloted by Gabriela Baez, 30, Evren Ergin, 37, and Maneesh Deshpande, 40. The group, which moved from Lehman Brothers following its acquisition last month by Barclays Capital’s parent, publishes “comprehensive reports that provide detailed antitrust and regulatory analysis, and analysis of other aspects that affect two companies’ ability to complete a merger,” explains one buy-side enthusiast. Case in point: the team’s October 2007 analysis of Finnish mobile phone manufacturer Nokia Corp.’s bid to buy Navteq Corp., a Chicago-based provider of digital maps, for $8.1 billion. Many analysts predicted that the deal would fail to win regulatory approval from the European Union because of antitrust concerns, and those concerns caused Navteq’s stock to trade well below the $78-per-share bid price. The team assured investors the deal would go through, and it did, closing in July. New co-leader Phillip Mackintosh helps Edward Tom steer the Credit Suisse squad up one notch to second place. In June the team published “When Oil Hell Breaks Loose,” predicting that oil prices were about to plunge and advising investors to write short-dated call options on oil exploration and production stocks. By mid-September the price of oil had fallen 22.2 percent, and E&P stocks were down 32.0 percent. Slipping one rung to third place is the Goldman, Sachs & Co. quartet now led by John Marshall, following Maria Grant’s January promotion to deputy director of U.S. equities research. In July the team recommended buying call options on Amgen — a biotechnology giant headquartered in Thousand Oaks, California — in anticipation of the stock’s gaining on news of favorable results from a clinical study of its osteoporosis drug, Denosumab. Amgen’s share price was up 25.1 percent in mid-September.

返回今年最好的分析师

回到排名